Bayer AGXSWX:BAYN 54 EBIT per Share is CHF-0.00 as of Mar. 2026. GuruFocus rates XSWX:BAYN with a GF Score™ of 54/100 and a GF Value™ of CHF24.74 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 809 Drug Manufacturers companies, Bayer AG ranks worse than 71.32% on this metric.
Bayer AG's EBIT per Share for the
three
months ended in Mar. 2026 was CHF3.21.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF-0.00.
During the past 12 months, the average EBIT per Share Growth Rate of Bayer AG was 186.90% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -5.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Bayer AG's EBIT per Share or its related term are showing as below:
XSWX:BAYN'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -40.3 Med: 5.5 Max: 23.1
Current: -5.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Bayer AG was 23.10% per year. The lowest was -40.30% per year. And the median was 5.50% per year.
XSWX:BAYN's 3-Year EBIT Growth Rate is ranked worse than 71.32% of 809
companies
in the Drug Manufacturers industry
Industry Median: 7.6
vs XSWX:BAYN: -5.80
Bayer AG's EBIT for the
three
months ended in Mar. 2026 was CHF3,152 Mil.
Bayer AG (XSWX:BAYN) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Bayer AG EBIT per Share Related Terms
Bayer AG EBIT per Share Historical Data
* Premium members only.
The historical data trend for Bayer AG's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bayer AG (XSWX:BAYN) has a EBIT per Share of CHF-0.00 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bayer AG and its competitors. According to the industry distribution chart, Bayer AG ranks #577 out of 809 companies in the Drug Manufacturers industry, placing it in the top 71.3%.
Is Bayer AG's EBIT per Share too high?
Bayer AG's current EBIT per Share is CHF-0.00. Based on the distribution chart, Bayer AG ranks #577 out of 809 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bayer AG has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's EBIT per Share compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Bayer AG ranks #577 out of 809 companies for EBIT per Share. This places Bayer AG in the lower half of its industry. The industry median EBIT per Share is 7.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.60, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bayer AG and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bayer AG's current EBIT per Share is CHF-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.74, compared to a current price of CHF42.49 — trading 71.7% above its estimated fair value. The current EBIT per Share is CHF-0.00. Bayer AG's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current EBIT per Share is CHF-0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (XSWX:BAYN) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of CHF42.49 is trading 71.7% above its estimated GF Value™ of CHF24.74.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for XSWX:BAYN:
EBIT per Share: CHF-0.00
GF Value™: CHF24.74 vs. price of CHF42.49 (71.7% above fair value)
No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
54GF Score
Get the complete analysis for XSWX:BAYN
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BAYN has been successfully added to your 
